Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 1/20 | 0.69 |
| ▸ | ECE1 | P42892 | 6/20 | 0.67 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.66 |
| ▸ | ANPEP | P15144 | 3/20 | 0.66 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.63 |
| ▸ | IL1RN | P18510 | 2/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7327655 | 1.00 | PYGB (0.69) | PYGBECE1ERAP2ANPEPERAP1 | |
| SCHEMBL7321746 | 0.90 | LTA4H (0.63) | ECE1ERAP2ANPEPERAP1ACE | |
| SCHEMBL7306489 | 0.89 | ERAP2 (0.68) | PYGBECE1ERAP2ANPEPERAP1 | |
| SCHEMBL7321552 | 0.89 | ACE (0.67) | ECE1ERAP2ANPEPERAP1ACE | |
| SCHEMBL7315009 | 0.87 | ERAP2 (0.64) | PYGBECE1ERAP2ANPEPERAP1 | |
| SCHEMBL12433272 | 0.85 | GHSR (0.59) | ECE1ERAP2ANPEPERAP1ACE | |
| SCHEMBL12511244 | 0.85 | GHSR (0.59) | ECE1ERAP2ANPEPERAP1ACE | |
| SCHEMBL13853026 | 0.85 | GHSR (0.59) | ECE1ERAP2ANPEPERAP1ACE | |
| SCHEMBL29376293 | 0.85 | ACE (0.61) | ECE1ERAP2ANPEPERAP1ACE | |
| SCHEMBL12433274 | 0.85 | GHSR (0.59) | ECE1ERAP2ANPEPERAP1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | PYGB 928/4885ECE1 3659/4885ERAP2 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.